Cardiac troponin T (cTnT) and cardiac troponin I (cTnI) were measured in 198 patients with renal dysfunction [132 men: median (range) age 66.1 (8.2-90.3) years]. cTnT was measured by two methods: ELISA and Enzymun (Boehringer Mannheim UK, Lewes, UK), both with a detection limit of 0.05 pg/L in 179 and 78 patients, respectively. cTnI was measured in 80 patients by the OPUS plus and OPUS Magnum systems (Dade-Behring, Milton Keynes, UK) with a detection limit of 0.5 pg/L.
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There is a high prevalence of cardiovascular complications in patients receiving renal replacement therapy.' The precise genesis of these are unknown, but hypertension, problems in fluid and electrolyte balance, metabolic abnormalities, including hyperlipidaemia and a direct toxic cardiomyopathy all contribute.2 We have measured cardiac troponin T (cTnT) and cardiac troponin I (cTnI) in the serum of patients with renal dysfunction to see if cardiac troponins were detectable and if they correlated with any other clinical or biochemical findings.
METHODS
Patients were classified as having chronic renal impairment (CRI, creatinine 120-200 pmol/L, Correspondence: Dr. P 0 Collinson. G F R 40-60 mL/min), chronic renal Failure (CRF, creatinine > 200 pmol/L, G F R < 40 mL/ min), acute renal failure (ARF, creatinine exceeding 500 pmol/L, of acute onset) including a subgroup requiring continuous veno-venous haemodiafiltration (CVVHD) as part of organ system support for multiple organ failure, and CRI requiring haemodialysis (HD). All patients had no evidence of active ischaemic heart disease by routine clinical investigations (clinical features, electrocardiography and echocardiography as appropriate).
CRI and CRF patients Blood samples were obtained from patients attending the renal clinic and inpatients at a district general hospital. In only 5 patients was diabetes mellitus considered to be the cause of renal dysfunction, so this sub-population was not studied separately.
ARF patients
Blood samples were obtained from patients with A R F both from in-patients and from those admitted to the intensive care unit (ICU) for CVVHD. Patients admitted to the ICU and commenced on CVVHD had developed acute renal failure as part of the multiple organ failure (MOF) syndrome. In those who were commenced on CVVHD, samples were obtained in the early period of treatment
HD patients
Blood samples were obtained from patients with chronic renal dysfunction participating in a renal replacement programme and receiving intermittent HD. Samples were obtained before and after dialysis.
Venous blood samples without anti-coagulant [plain tubes or tubes containing separator gel (as this is known not to cause assay interference)] were obtained from patients using conventional vacutainer tubes (Vacutainer, Becton-Dickinson, Oxford, UK). Serum samples were analysed immediately or stored at 4°C for analysis within 48 h, or stored at -20°C if analysis was delayed.
A total of 198 patients (132 men) were studied: median age 66.1 years (range 8.2-90.3) in two sequential cohorts. In the first cohort, (n = 1 17) cTnT, urea, creatinine, creatinine kinase (CK) and CK-MB were measured. In the second cohort (n = 8 l), cTnT, cTnI, urea and creatinine were measured. cTnT was measured by ELISA using the ES 300 automated immunoassay system (Boehringer Mannheim UK, Lewes, UK) as previously described3 using the original ELISA (first cohort) and both the original ELISA and the re-formulated Enzymun method, with an enhanced detection antibody (second cohort). The detection limit for both assays was O.OSpg/L. cTnI was measured using the Opus Plus or Opus Magnum system (Behring Diagnostics, Milton Keynes, UK). This has a detection limit of 0.5pg/L. A total of 179 ELISA cTnT, 78 Enzymun cTnT and 80 cTnI measurements were performed. CK (measured at 37"C, reference interval 0-200 p/L), urea (urease method, reference interval 2.8-5.2 mmol/L) and creatinine (alkaline picrate, reference interval 60-120 pmol/L) were measured using a Technicon AXON (Bayer Technicon, Basingstoke, UK) by the manufacturer's recommended methods. CK-MB mass concentration was measured by a microparticle assay (Abbott Diagnostics, Maidenhead, UK, reference interval < 5 pg/L).
RESULTS

Comparison of ELISA and Enzymun methods
cTnT was detectable in the serum of patients with renal dysfunction in 113/179 (63.1%) and 33/78 (42.3%) by the ELISA and Enzymun methods, respectively. Comparison of values in patients tested by both methods by Mann-Whitney U test showed no significant difference (n=65, U=1.4087, P=O.159). There was marked discordance between results in only one case. Comparison of methods by Deming regression and Altman and Bland plots showed good agreement between methods when this single outlier was excluded (n = 64, r = 0.9792, slope = 0.8038, intercept = -0.0443). Twelve of 65 cases had cTnT above the discriminant of 0.2pg/L by ELISA. This reduced to 5/65 with the second generation (Enzymun) assay [not significant, Fisher's exact probability test].
Relationship between cTnT values and urea, creatinine, CK and CK-MB
By both ELISA and Enzymun methods, there was an association of cTnT with serum urea and creatinine concentration (Spearman rank correlation). However, by Deming regression, this association was not predictive for creatinine or for urea. By Spearman Rank correlation, no association was seen between cTnI values and creatinine or urea. For both ELISA and Enzymun methods, there was no association between cTnT and CK or CK-MB (Spearman Rank correlation. In 97 cases, CK was less than 200 U/L and CK-MB less than 5 pg/L with cTnT exceeding 0.2 pg/L in 3 1. CK exceeded 200 U/L in 20 cases, with elevation of CK-MB above lOpg/L in four and cTnT detectable in 13, but exceeding 0.2 pg/L in 11. CK exceeded 400 U/L in eight cases, all of whom had detectable cTnT, seven exceeding 0.2 pg/L. In four cases, CK-MB exceeded lOpg/L. In all four cases, cTnT was detectable, exceeding 0.2pg/L in two. Of these four cases with elevated CK-MB, only two patients, both with multiple organ failure, showed a consistent pattern of elevation of CK, CK-MB and cTnT suggestive of cardiac damage by current criteria.
Pattern of cTnT and cTnI in different patient categories
Data for cTnT (ELISA and Enzymun) and cTnI are summarized in Table 1 . ELISA and Enzymun cTnT values were significantly higher as renal dysfunction increased from the CRI to C R F and H D groups (P<O.OOOl and 0.0039, Mann-Whitney, respectively). In patients with ARF, cTnT results (ELISA and Enzymun) were significantly higher than all other groups (P<O.OOOl, Mann--Whitney). There was no statistically significant difference in cTnT values between pre-and post-dialysis samples. In the CRI, C R F and H D groups, median cTnT ELISA and Enzymun was below 0.2,~ig;L (our upper reference limit). In patients with A R F requiring haemofiltrdtion, the median cTnT ELISA was 0.94 pg/L (range < 0.05-1 7,24pg/L), significantly higher than the CRI, C R F and H D groups (P<O.OOOI, Mann-Whitney). Thirty-six patients in this group had multiple organ failure. Thirty-fivc out of 36 patients had detectable cTnT, which was above 0.2pg/L in 30. The one patient who did not have detectable cTnT had hepatorenal syndrome, so the renal failure had a different pathophysiology. The cTnT ELISA data are shown in Fig. 1 .
A similar trend was seen in the cTnI results. All median values were below the detection limit for the assay except for the A R F group. There was no statistically significant difference between the CRI, C R F and H D groups. The A R F group however showed significantly higher values than the CRI (P=0.0229, Mann-Whitney) and C R F ( P = 0.0364, Mann-Whitney) groups.
Comparison of cTnT and cTnI
Comparison of cTnT Enzymun and cTnI is shown in Fig. 2 . cTnI was detectable in patients with renal dysfunction 17/80 (21.3%), but in proportionally fewer cases. We have found a cut-off of I pg/L to give equivalent diagnostic sensitivity and specificity for both cTnI and cTnT for the diagnosis of ischaemic cardiac damage and have not detected cTnl in the serum of normal healthy adults. The manufacturer quotes a diagnostic cut-off of 2pg/L. The distribution data for cTnT ELISA, cTnT Enzymun and cTnI are shown in Table 2 for all patients in whom all data were available according to selected cut-offs. There is no statistically significant difference between the ELISA and Enyymun cTnT results in any of the patient groups studied (Fisher's exact probability test). At a diagnostic cut-off for cTnl of 1 pg/ L, there is similarly no difference between the ELISA cTnT, Enzymun cTnT and cTnI results. At a diagnostic cut-off for cTnI of 2pg/L, the results for cTnT ELISA and cTnI are statistically significantly different for the C R F and H D group (P=0.027, C R F group, P=0.0222 H D group, Fisher's exact probability test). For the Enzymun cTnT however, the results are not statistically significantly different at either cutoff for cTnl.
Serial measurements of cTnT were performed in three patients with A R F in the ICU. Recovery with return of normal renal function and hospital discharge was accompanied by a fall in cTnT levels to undetectable values. This is illustrated for one patient in Fig. 3 .
DISCUSSION
cTnT was detectable in patients with renal dysfunction. Maximal elevation of cTnT was seen in patients with acute renal failure associated with multi-organ failure (MOF). Detectable cTnT in renal failure may represent unsuspected myocardial damage, and in patients with MOF may be a cardiac manifestation of the syndrome. Serial measurement in patients with MOF who survived showed falls in cTnT to undetectable levels on recovery.
cTnI has been measured in patients with renal failure and one case of elevated cTnI associated with cardiac regional wall motion abnormality r e p~r t e d .~
Hafner measured cTnI and cTnT in patients with renal dysfunction receiving H D and reported elevation of cTnT in 46.3% but cTnI in only 1.5%. This study used the ELISA cTnT method. A recent case report6 documented discordant results between cTnT and cTnI in patients with rhabdomyolysis. This was due to assay interference in the original formulation of the ELISA, which occurs in the presence of skeletal muscle trauma releasing skeletal troponin T (sTnT). In the original characterization of the assay, Katus et al.' found 3.6% cross reaction but non-specific binding at high concentrations of purified troponin. This did not occur when serum samples were used. The second antibody is known to be less cardiac specific. ' We have found that there is a case of severe interference in skeletal muscle damage because of high sTnT levels. There is non-specific binding of sTnT to the assay tube wall so there will be subsequent detection by the second, non-cardiac specific, anti-troponin T antibody. A reformulation of the ELISA cTnT assay in the second generation Enzymun system (which has two cTnT specific antibodies) and the whole blood rapid assay (which uses a cTnT specific detection antibody) does not suffer from this interferen~e.~.~ Recent studies with the Enzymun assay have confirmed that there is concordance between elevations of cTnT and cTnI in patients with renal dysfunction.lO." There are proportionally more patients who have elevated cTnT than cTnI, but the difference is not as absolute as was originally suggested.I0-l2 Direct comparison of cTnT ELISA, cTnT Enzymun and cTnI measured by the Dade Stratus method in patients with renal failure showed 21/52 elevated cTnT by ELISA, 15/52 elevations by Enzymun and 7/52 elevations of cTnI.'" In a well-studied cohort of 16 patients undergoing renal replacement therapy considered not to have cardiac disease followed up for 1 year, Apple and co-workers found elevation of cTnT in eight and cTnI in three. There were three cardiac deaths, all of whom had positive cTnT but only 2/3 had positive cTnI.12
The reason for the difference between cTnT and cTnI assays in patients with renal dysfunction requires explanation, but may represent different assay sensitivities. There are different assay cut-offs for cTnI for the studies quoted: 3.1 mg/L4 and 2.1 mg/L.' The manufacturers quote different cut-offs of 1 pg/L for the Dade Stratus and 0.1 mg/L for the Sanofi Pasteur cTnI assays compared with 0.1-0.2mg/L for cTnT. The difference is of an order of magnitude. There are clearly issues around the standardization of cTnI assays and a need to establish an appropriate reference cut-off. In addition, recent studies have shown differential stability of cTnI with cTnI-troponin C complexes. There are currently no data on what the individual assays are measuring, and whether there is measurement of cTnI alone or troponin I complexes with troponins C or T. Recent studies have also shown that phosphorylation of cTnI occurs, which may also affect the assays. Epitope stability for cTnI has not been characterized, whereas cTnT is stable under routine clinical conditions. Subclinical myocardial damage may be present in patients with renal dysfunction, undetectable by current methods of cardiac imaging. This makes the definition of a reference population to determine if this is a false positive for cTnT or a false negative for cTnI more difficult.
The possibility of re-expression of cTnT in skeletal muscle in chronic renal failure cannot be categorically excluded. A recent report has shown that in situations of chronic inflammation (polymyositis) and muscle damage with regeneration (muscular dystrophy), re-expression of cTnT, like CK-MB, can occur.13 In this study, cTnT was also detected in normal skeletal muscle biopsies. Previous studies have not detected the expression of fetal isoform cTnT mRNA in adult skeletal muscle'4 by polymerase chain reaction methodology, which suggests that the immuno-staining methods used may show cross reaction with skeletal muscle TnT. In a recent study, Apple and colleagues12 performed western blot analysis of muscle biopsy specimens from five patients receiving renal replacement therapy and were able to detect a cTnT isoform in the biopsy samples. However, they did not use the same antibody that is used in the Enzymun method. Hence, it is not clear which isoform was being re-expressed. This subject has been recently reviewed in detail."
In conclusion, elevations of both cTnT and cTnI are found in patients with renal dysfunction, representing a manifestation of the disease process. In routine clinical practice this is unlikely to create a problem as these patients will form a minority of those investigated for suspected cardiac disease. The differential diagnosis of the patient with CRF or receiving HD in whom AM1 is suspected will require serial measurement of cTnT or cTnI and a demonstration of temporal changes. Neither a single negative nor a single positive cTn measurement can be used to rule in or rule out myocardial infarction in this patient group. Prospective studies are required to establish the clinical significance of cTn levels in patients with renal dysfunction, relating the presence of cTnT and cTnI to the future development of cardiac disorders or other adverse events.
